Cargando…

Combination of sacubitril/valsartan and blockade of the PI3K pathway enhanced kidney protection in a mouse model of cardiorenal syndrome

AIMS: Angiotensin receptor-neprilysin inhibitor (ARNI) is an established treatment for heart failure. However, whether ARNI has renoprotective effects beyond renin-angiotensin system inhibitors alone in cardiorenal syndrome (CRS) has not been fully elucidated. Here, we examined the effects of ARNI o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsukamoto, Shunichiro, Wakui, Hiromichi, Uehara, Tatsuki, Shiba, Yuka, Azushima, Kengo, Abe, Eriko, Tanaka, Shohei, Taguchi, Shinya, Hirota, Keigo, Urate, Shingo, Suzuki, Toru, Yamada, Takayuki, Kinguchi, Sho, Yamashita, Akio, Tamura, Kouichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630100/ https://www.ncbi.nlm.nih.gov/pubmed/37941728 http://dx.doi.org/10.1093/ehjopen/oead098

Ejemplares similares

Author Correction: Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization
por: Abe, Eriko, et al.
Publicado: (2022)

Angiotensin II type-1 receptor-associated protein interacts with transferrin receptor-1 and promotes its internalization
por: Abe, Eriko, et al.
Publicado: (2022)

Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy
por: Taguchi, Shinya, et al.
Publicado: (2021)

Aristolochic Acid Induces Renal Fibrosis and Senescence in Mice
por: Urate, Shingo, et al.
Publicado: (2021)

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection
por: Tsukamoto, Shunichiro, et al.
Publicado: (2023)

Comparative Efficacy of Pharmacological Treatments for Adults With Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Tsukamoto, Shunichiro, et al.
Publicado: (2022)

Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease
por: Tsukamoto, Shunichiro, et al.
Publicado: (2021)

Effects of a High-Protein Diet on Kidney Injury under Conditions of Non-CKD or CKD in Mice
por: Tanaka, Shohei, et al.
Publicado: (2023)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
por: Wang, Shuangcui, et al.
Publicado: (2023)

SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan
por: Kanai, Daisuke, et al.
Publicado: (2022)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
por: Uneda, Kazushi, et al.
Publicado: (2021)

Angiotensin II type 1 receptor-associated protein deficiency attenuates sirtuin1 expression in an immortalised human renal proximal tubule cell line
por: Yamaji, Takahiro, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic on physical and psychological activities in elderly patients with hypertension
por: Azushima, Kengo, et al.
Publicado: (2022)

Blunted humoral immune response to the fourth dose of BNT162b2 COVID-19 vaccine in patients undergoing hemodialysis
por: Kanai, Daisuke, et al.
Publicado: (2023)

Tissue xanthine oxidoreductase activity in a mouse model of aristolochic acid nephropathy
por: Ishii, Takeo, et al.
Publicado: (2021)

Effects of rikkunshito on renal fibrosis and inflammation in angiotensin II-infused mice
por: Azushima, Kengo, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Effects of Rikkunshito treatment on renal fibrosis/inflammation and body weight reduction in a unilateral ureteral obstruction model in mice
por: Wakui, Hiromichi, et al.
Publicado: (2020)

Adipocyte‐Specific Enhancement of Angiotensin II Type 1 Receptor‐Associated Protein Ameliorates Diet‐Induced Visceral Obesity and Insulin Resistance
por: Azushima, Kengo, et al.
Publicado: (2017)

Systematic Review of the Association Between Worsening Renal Function and Mortality in Patients With Acute Decompensated Heart Failure
por: Yamada, Takayuki, et al.
Publicado: (2020)

Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease
por: Uehara, Tatsuki, et al.
Publicado: (2023)

Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
por: Ohsawa, Masato, et al.
Publicado: (2015)

Addition of Aliskiren to Angiotensin Receptor Blocker Improves Ambulatory Blood Pressure Profile and Cardiorenal Function Better than Addition of Benazepril in Chronic Kidney Disease
por: Ohsawa, Masato, et al.
Publicado: (2013)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Early Enhanced Leucine-Rich α-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice
por: haku, Sona, et al.
Publicado: (2018)

Effects of ATRAP in Renal Proximal Tubules on Angiotensin‐Dependent Hypertension
por: Kinguchi, Sho, et al.
Publicado: (2019)

ATRAP Expression in Brown Adipose Tissue Does Not Influence the Development of Diet-Induced Metabolic Disorders in Mice
por: Ohki, Kohji, et al.
Publicado: (2017)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
por: Yamada, Takayuki, et al.
Publicado: (2021)

Efficacy and safety of sacubitril/valsartan after switching from azilsartan in hemodialysis patients with hypertension
por: Iwashima, Yoshio, et al.
Publicado: (2023)

Angiotensin II Type 1 Receptor‐Associated Protein Regulates Kidney Aging and Lifespan Independent of Angiotensin
por: Uneda, Kazushi, et al.
Publicado: (2017)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9milaehh8ne98bk8s63tsdupgc